In Brief: Chiron
Chiron: Company will take a charge against earnings for the third quarter for the carrying value reduction of its idle fill and finishing facility in Puerto Rico. Appraisal is not complete but Chiron estimates that a $25 mil. write-down will be taken. The company is considering selling the facility. It was built for the manufacture of Betaseron (interferon beta-1b) for Berlex but never went on-line; need for Betaseron did not grow as predicted to require a second facility...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth